Effect and safety of dual anti-human epidermal growth factor receptor 2 therapy compared to monotherapy in patients with human epidermal growth factor receptor 2-positive breast cancer: a systematic review

Zhang, Xiao; Zhang, Xin-Ji; Zhang, Tian-Yi; Yu, Fei-Fei; Wei, Xin; Li, Ye-Sheng; He, Jia

doi:10.1186/1471-2407-14-625

Table 1 Character of the included studies

From: Effect and safety of dual anti-human epidermal growth factor receptor 2 therapy compared to monotherapy in patients with human epidermal growth factor receptor 2-positive breast cancer: a systematic review

Study	Phase	Treatment staus	Treatment arms	Pts no.	Dosage	Chemotherapy	Treatment duration	Median age	Jada score	Follow- up (m)
CHER-LOB²⁶ (2012)	2	Neoadjuvant	T	36	2 mg/kg weekly (loading 4 mg/kg)	Paclitaxel	26 weeks	50	5	NA
			L	39	1500 mg daily	Paclitaxel	26 weeks	49		NA
			L + T	46	1000 mg daily + 2 mg/kg weekly (loading 4 mg/kg)	Paclitaxel	26 weeks	49		NA
NeoALTTO²⁷ (2012)	3	Neoadjuvant	L	149	1500 mg daily	Paclitaxel	18 weeks	50	5	NA
			T	154	2 mg/kg weekly (loading 4 mg/kg)	Paclitaxel	18 weeks	49		NA
			L + T	152	1000 mg daily + 2 mg/kg weekly (loading 4 mg/kg)	Paclitaxel	18 weeks	50		NA
NSABP B-41²¹ (2012)	3	Neoadjuvant	T	177	2 mg/kg weekly (loading 4 mg/kg)	Paclitaxel	12 weeks	NA	4	NA
			L	171	1250 mg daily	Paclitaxel	13 weeks	NA		NA
			L + T	171	750 mg daily + 2 mg/kg weekly (loading 4 mg/kg)	Paclitaxel	14 weeks	NA		NA
NeoSphere²⁵ (2012)	2	Neoadjuvant	T	107	6 mg/kg q3w (loading 8 mg/kg)	Docetaxel	12 weeks	50	4	NA
			T + P	107	6 mg/kg q3w (loading 8 mg/kg) + 420 mg/kg q3w (loading 840 mg/kg)	docetaxel	13 weeks	50		NA
			T + P	107	6 mg/kg q3w (loading 8 mg/kg) +420 mg/kg q3w(loading 840 mg/kg)	NO	14 weeks	49		NA
			P	96	420 mg/kg q3w (loading 840 mg/kg)	docetaxel	15 weeks	49	4	NA
Holmes²⁸ (2012)	NA	Neoadjuvant	T	33	2 mg/kg weekly (loading 4 mg/kg)	FEC	26 weeks	NA		NA
			L	34	1250 mg daily	FEC	27 weeks	NA		NA
			L + T	33	750 mg daily + 2 mg/kg weekly	FEC	28 weeks	NA		NA
EGF104900²⁴ (2012)	3	Metastatic	L + T	148	1000 mg daily + 2 mg/kg weekly	No	Until progression or unacceptable toxicity	51	3	12.8
			L	148	1500 mg daily	No	Until progression or unacceptable toxicity	51		8.7
CLEOPATRA¹⁵ (2012)	3	Metastatic	P + T	402	6 mg/kg q3w (loading 8 mg/kg) + 420 mg/kg q3w (loading 840 mg/kg)	Docetaxel	Until progression or unacceptable toxicity	54	5	30
			Placebo + T	406	6 mg/kg q3w (loading 8 mg/kg)	Docetaxel	Until progression or unacceptable toxicity	54		30

Abbreviations: T Trastuzumab, L Lapatinib, P Pertuzumab, pts no patients number, mg milligram, kg kilogram, Pacl Paclitaxel, FEC Fluorouracil (5FU), epirubicin, and cyclophosphamide; q3w three-weekly, NA Not available, m month.

Back to article page

ISSN: 1471-2407

Contact us

Submission enquiries: bmccancer@biomedcentral.com
General enquiries: ORSupport@springernature.com

BMC Cancer

Contact us